CD8A and neoplasm: Another study also indicated that siRNA against PD-L1 or PD-L1 improved effector functions of tumor-specific CD4+ and CD8+ T cells in vitro (121), suggesting that PD-L1/PD-L2 siRNA is an exciting strategy to inhibit the immune suppressive tumor-specific T cells.